Skip to content

Predictive value of sleep monitoring on cognitive impairment after cerebral infarction

Predictive value of sleep monitoring on cognitive impairment after cerebral infarction

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039395
Enrollment
Unknown
Registered
2020-10-25
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sleep disorder

Interventions

Gold Standard:Sleep status were assessed by polysomnography and cognitive function assessed by Montreal cognitive test.
Index test:polysomnography

Sponsors

Shanghai Tianyou Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) The diagnosis of cerebral infarction was in accordance with the standard adopted by the 4th National Cerebrovascular Disease Conference of Neurology branch of Chinese Medical Association in 1995; 2) Aged >= 18 years; 3) The first onset was confirmed by CT or MRI; 4) Clear consciousness, no obvious aphasia and hearing impairment; 5) The vital signs and neurological symptoms were stable for 24 hours; 6) Acute stroke onset time <= 14 days; 7) There were no serious complications (malignant tumor, liver cirrhosis, renal insufficiency, heart failure, etc.); 8) They agreed to participate in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1) People with disturbance of consciousness due to any reason; 2) Severe aphasia or audiovisual impairment who cannot complete the questionnaire or scale assessment; 3) Patients with acute alcoholism that can cause dementia or dementia patients with a history of alcoholism or drug addiction; 4) Patients with brain injury, epilepsy, encephalitis, normal intracranial pressure hydrocephalus and other neurological diseases that can cause cognitive impairment; 5) Those who are taking antipsychotic, anti anxiety and hypnotic drugs.

Design outcomes

Primary

MeasureTime frame
improve;improve;improve;improve;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactWang Zongwen

Department of Neurology, Shanghai Tianyou Hospital

kevinwzw@126.com+86 19945751430

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026